9.20

0.66% 0.06

Theravance Biopharma Inc (TBPH)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$9.14

Aprire:

$9.13

Volume 24 ore:

288.74K

Relative Volume:

1.11

Capitalizzazione di mercato:

$460.00M

Reddito:

$62.02M

Utile/perdita netta:

$-45.65M

Rapporto P/E:

-10.00

EPS:

-0.92

Flusso di cassa netto:

$-9.60M

1 W Prestazione:

+2.45%

1M Prestazione:

+7.04%

6M Prestazione:

-3.36%

1 anno Prestazione:

-4.17%

Intervallo 1D:

$9.04

$9.37

Intervallo di 1 settimana:

$8.33

$9.37

Portata 52W:

$7.44

$10.90

Theravance Biopharma Inc Stock (TBPH) Company Profile

Nome

Theravance Biopharma Inc

Settore

Healthcare (1170)

Industria

Biotechnology (671)

Telefono

650-808-6000

Indirizzo

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

TBPH's Discussions on Twitter

Confronta TBPH con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TBPH Theravance Biopharma Inc	9.20	449.01M	62.02M	-45.65M	-9.60M	-0.92
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-08-06	Downgrade	Leerink Partners	Outperform → Market Perform
2024-04-12	Iniziato	BTIG Research	Buy
2024-01-08	Downgrade	Evercore ISI	Outperform → In-line
2022-05-23	Iniziato	SVB Leerink	Outperform
2021-11-05	Aggiornamento	JP Morgan	Underweight → Neutral
2021-09-15	Downgrade	JP Morgan	Overweight → Underweight
2021-08-25	Downgrade	Morgan Stanley	Overweight → Underweight
2021-08-24	Downgrade	Cowen	Outperform → Market Perform
2020-10-14	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Iniziato	JP Morgan	Overweight
2020-06-15	Iniziato	Morgan Stanley	Equal-Weight
2020-05-13	Iniziato	Cowen	Outperform
2020-01-08	Reiterato	H.C. Wainwright	Buy
2019-11-06	Aggiornamento	Robert W. Baird	Underperform → Neutral
2019-10-29	Iniziato	H.C. Wainwright	Buy
2018-03-29	Ripresa	Piper Jaffray	Overweight
2017-08-17	Iniziato	Evercore ISI	Outperform
2017-06-16	Iniziato	Cantor Fitzgerald	Overweight
2017-05-11	Reiterato	Needham	Buy
2016-12-21	Iniziato	Needham	Buy
2016-11-03	Iniziato	Piper Jaffray	Overweight
2016-10-12	Downgrade	Robert W. Baird	Neutral → Underperform
2016-08-03	Downgrade	BofA/Merrill	Neutral → Underperform
2016-06-20	Iniziato	Guggenheim	Buy
2016-06-20	Reiterato	Leerink Partners	Outperform
2016-05-12	Iniziato	Leerink Partners	Outperform
2016-05-05	Downgrade	BofA/Merrill	Buy → Neutral
2015-02-03	Aggiornamento	Robert W. Baird	Underperform → Neutral

Mostra tutto

Theravance Biopharma Inc Borsa (TBPH) Ultime notizie

May 16, 2025

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by StockNews.com - Defense World

May 16, 2025

May 15, 2025

When (TBPH) Moves Investors should Listen - news.stocktradersdaily.com

May 15, 2025

May 13, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conf - GuruFocus

May 13, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune

May 13, 2025

Price T Rowe Associates Inc. MD Buys 9,315 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 13, 2025

Dimensional Fund Advisors LP Acquires 95,304 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

May 13, 2025

May 12, 2025

We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation - simplywall.st

May 12, 2025

May 10, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at th - GuruFocus

May 09, 2025

Theravance Biopharma, Inc. Announces Ampreloxetine Presentations At the International MSA Congress - marketscreener.com

May 09, 2025

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - Yahoo Finance

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News - GuruFocus

May 09, 2025

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - PR Newswire

May 09, 2025

Theravance Biopharma: Promising Future with Strong Product Pipeline and Market Expansion - TipRanks

May 09, 2025